Acuta Capital Partners’s Q32 Bio QTTB Stock Holding History

Acuta Capital Partners’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-4,389	Closed	-$1.48M	–	75
2018 Q1	$1.48M	Buy	+4,389	New	+$1.48M	0.24%	38

Other funds holding QTTB

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acuta Capital Partners's QTTB Position: Q2 2018 in Review

Acuta Capital Partners sold out of Q32 Bio (QTTB) in Q2 2018, closing a stake of 4,389 shares — an estimated $1.48M sold.

Acuta Capital Partners first reported a position in QTTB in Q1 2018 and held it in 1 quarter. The position peaked at $1.48M in Q1 2018. 53 funds tracked by Wall St. Rank hold QTTB as of Q2 2018.

Acuta Capital Partners reported no remaining Q32 Bio position as of Q2 2018 after selling out during the quarter.
Acuta Capital Partners sold 4,389 Q32 Bio shares in Q2 2018, an estimated $1.48M.
Acuta Capital Partners first reported a position in Q32 Bio in Q1 2018 and held it in 1 quarter.
Acuta Capital Partners's Q32 Bio position peaked at $1.48M in Q1 2018.
53 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2018.

Based on Acuta Capital Partners's 13F filing for Q2 2018, filed 15 Aug 2018.